Management of psychotic aspects of Parkinson's disease

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 8, 1999, Pages 42-53

  Juncos, J L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DONEPEZIL; GABAPENTIN; LAMOTRIGINE; LITHIUM CARBONATE; MOLINDONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SELEGILINE; TACRINE; THIORIDAZINE; VALPROIC ACID;

AFFECTIVE NEUROSIS; COGNITIVE DEFECT; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SIDE EFFECT; SLEEP DISORDER; SYMPTOMATOLOGY;

ALGORITHMS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; CLOZAPINE; COMORBIDITY; DECISION TREES; DIBENZOTHIAZEPINES; HUMANS; PARKINSON DISEASE; PIRENZEPINE; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS;

EID: 0032940307     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Martilla RJ. Epidemiology. In: Koller WC, ed. Handbook of Parkinson's Disease. New York, NY: Dekker; 1987:35-51
2. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in community population of older people. N Engl J Med 1996;334:71-76
3. DeLong MR, Juncos JL. Diseases of the extrapyramidal system. In: Rosenberg RN, Pleasure DE, eds. Comprehensive Neurology. 2nd ed. New York, NY: John Wiley & Sons; 1998:387-414
4. Quinn N. Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry 1989;52(suppl):78-89
5. Wenning GK, Ben SY, Magalhaes M, et al. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994; 117:835-845
6. Tolosa E, Duvoisin R, Cruz-Sanchez FF. Progressive Supranuclear Palsy: Diagnosis, Pathology, and Therapy. New York, NY: Springer-Verlag; 1994
7. Galasko D, Katzman R, Salmon DP, et al. Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 1996;31:166-175
8. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987;37:754-760
9. Bergeron C, Pollanen M. Lewy bodies in Alzheimer's disease: one or two diseases? Alzheimer Dis Assoc Disord 1989;3:197-204
10. Armstrong TP, Hansen LA, Salmon DP, et al. Rapidly progressive dementia in a patient with the Lewy body variant of Alzheimer's disease. Neurology 1991;41:1178-1180
11. Cercy SP, Bylsma FW. Lewy bodies and progressive dementia: a critical review and meta-analysis. J Int Neuropsychol Soc 1997;3:179-194
12. Watts RL, Koller WC. Movement Disorders: Neurologic Principles and Practice. 1st ed. New York, NY: McGraw-Hill; 1997
13. Starkstein SE, Mayberg HS, Leiguarda R, et al. A prospective longitudinal study of depression, cognitive decline and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:377-382
14. Goetz C, Stebbins G. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229
15. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-716
16. Celesia G, Barr A. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970;3:193-200
17. Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65:115-138
18. Peyser CE, Naimark D, Zuniga R, et al. Psychoses in Parkinson's disease. Semin Clin Neuropsychiatry 1998;3:41-50
19. Olanow CW, Koller WC. An algorithm for the management of Parkinson's disease: treatment guidelines. Neurosurgery 1998;50(suppl 3):S1-S57
20. Lipowski ZJ. Delirium in the elderly patient. N Engl J Med 1989;320: 578-582
21. Brown FW. The neurobiology of late-life psychosis. Crit Rev Neurobiol 1993;7:275-289
22. Parsa MA, Simon M, Dubrow C, et al. Psychiatric manifestations of olivoponto-cerebellar atrophy treated with clozapine. Int J Psychiatry Med 1993;23:149-156
23. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry 1998;59(suppl 1):5-10
24. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990;85:119-146
25. Kalivas PW, Barnes CD. Limbic Motor Circuits and Neuropsychiatry. London, England: CRC Press; 1993
26. Doraiswamy M, Martin W, Metz A, et al. Psychosis in Parkinson's disease: diagnosis and treatment. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:835-846
27. Klawans HL. Levodopa-induced psychosis. Psychiatr Ann 1978;8: 447-451
28. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675
29. Stein MB, Heuser IJ, Juncos JL, et al. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990;147:217-220
30. Juncos JL. Levodopa: pharmacology, pharmacokinetics and pharmacodynamics. Neurol Clin 1992;10:487-509
31. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. Q J Med 1980;49:283-293
32. Nausieda P, Tanner C, Klawans H. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol 1983;37: 23-32
33. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(suppl 10):55-62
34. Mayeux R, Stern Y, Rosen J, et al. Depression, intellectual impairment, and Parkinson's disease. Neurology 1981;31:645-650
35. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988; 1:24-36
36. Lieberman A, Dziatolowski M, Kupersmith M. Dementia in Parkinson's disease. Ann Neurol 1979;6:355-359
37. Hughes A, Daniel S, Blankson S, et al. A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148
38. Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, et al. Diffuse Lewy body disease and progressive dementia. Neurology 1988;38: 1520-1528
39. Byrne EJ, Lennox G, Lowe J, et al. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989;52:709-717
40. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8
41. Kuzuhara S, Yoshimura M. Clinical and neuropathological aspects of diffuse Lewy body disease in elderly. Adv Neurol 1993;60:464-469
42. Samuel W, Galasko D, Masliah E, et al. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:44-52
43. McShane R, Keene J, Gedling K, et al. Hallucinations. Cortical Lewy Body Pathology, Cognitive Function and Neuroleptic Use in Dementia. New York, NY: Cambridge; 1996:85-98
44. Morris S, Olichney J, Corey-Bloom J. Psychosis in dementia with Lewy bodies. Semin Clin Neuropsychiatry 1998;3:51-60
45. Perry R, Irving D, Tomlinson B. Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 1990;100:223-233
46. Klatka LA, Elam DL, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 1996;47:1148-1152
47. Ala TA, Yang KH, Sung JH, et al. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997;62:16-21
48. Crystal HA, Dickson DW, Lisardi JE, et al. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990;40:1523-1528
49. McKeith IG, Perry RH, Fairbairn AF, et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;22:911-922
50. Louis ED, Goldman JE, Powers JM. Parkinsonism features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord 1995; 10:188-194
51. Olichney JM, Hofstetter CR, Salmon D, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease [letter]. Neurology 1997; 48:A141
52. Del-Ser T, Munoz DG, Hachinsi V. Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. Neurology 1996;46:682-686
53. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-678
54. Chacko RC, Hurley RA, Jancovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 1993;5:206-208
55. Allen RL, Walker Z, D'Ath PJ, et al. Risperidone for psychotic and behavioral symptoms in Lewy body dementia [letter]. Lancet 1995;346:185
56. Rourke D, Druckenbrod RW. Possible association between donepezil and worsening Parkinson's disease [letter]. Ann Pharmacother 1998;32: 610-611
57. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1996;61:324-325
58. Cummings JL. Depression and Parkinson's disease. Am J Psychiatry 1992; 149:443-454
59. Starkstein SE, Preziosi TJ, Bolduc PL, et al. Depression in Parkinson's disease. J Nerv Ment Dis 1990;178:27-31
60. Cohen-Cole S, Woodard J, Juncos JL, et al. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996;8:20-25
61. Lieberman A. Depression in Parkinson's disease. BNI Quarterly 1997;13: 27-33
62. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. In: Weiner WJ, Lang AE, eds. Behavioral Neurology of Movement Disorders. New York, NY: Raven Press; 1995:61-84
63. Mayberg HS, Solomon DH. Depression in Parkinson's disease: a biochemical and organic viewpoint. In: Weiner WJ, Lang AE, eds. Behavioral Neurology of Movement Disorders. New York, NY: Raven Press; 1995: 49-60
64. Mayeux R, Stern Y, Williams JBW, et al. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986;143:756-759
65. Taylor AE, Saint-Cyr JA, Lang AE, et al. Parkinson's disease and depression: a critical reevaluation. Brain 1986;109:279-292
66. Brown RG, MacCarthy B, Gotham AM, et al. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med 1988;18: 49-55
67. Robins AH. Depression in patients with parkinsonism. Br J Psychiatry 1976;128:141-145
68. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986;36: 1130-1133
69. Menza MA, Sage J, Marshall E, et al. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 1990;5:148-151
70. Jenkins RB, Groh RH. Mental symptoms in Parkinson patients treated with L-DOPA. Lancet 1970;2:177-180
71. Sweet R, McDowell F, Feigenson J, et al. Mental symptoms in Parkinson's disease during chronic treatment with levodopa. Neurology 1976;26: 205-310
72. Young BK, Camicioli R, Ganzini L. Neuropsychiatrie adverse effects of antiparkinsonian drugs: characteristics, evaluation and treatment. Drugs Aging 1997;10:367-383
73. Arvanitis LA, Miller BG, Kowalcyk BB. Efficacy of Seroquel (quetiapine fumarate) in affective symptoms of schizophrenia [abstract]. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Waikoloa, Hawaii
74. Tollefson GD, Sanger TM, Lu U, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-258
75. Nausieda PA, Werner WJ, Kaplan LR, et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of levodopa psychosis. Clin Neuropharmacol 1982;5:183-194
76. Cornella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993;34:710-714
77. Smith MC, Ellgring H, Oertel WH. Sleep disturbances in Parkinson's disease patients and spouses. J Am Geriatr Soc 1997;45:194-199
78. Schenck CH, Bundie SR, Patterson AL, et al. Rapid eye movement sleep behavior disorders. JAMA 1987;257:1786-1789
79. Bliwise DL. Treating insomnia: pharmacological and nonpharmacological approaches. J Psychoactive Drugs 1991;23:335-341
80. Krueger BR. Restless legs syndrome and periodic movements of sleep. Mayo Clin Proc 1990;65:999-1006
81. Lugaresi E, Cirignotta F, Coccagna G, et al. Nocturnal myoclonus and restless legs syndrome. Adv Neurol 1986;43:295-307
82. Bliwise DL, Watts RL, Watts N, et al. Disruptive nocturnal behavior in Parkinson's disease and Alzheimer's disease. J Geriatr Psychiatry Neurol 1995;8:107-110
83. Menza MA, Rosen RC. Sleep in Parkinson's disease: the role of depression and anxiety. Psychosomatics 1995;36:262-266
84. Uitti RJ, Tanner CM, Rajput AH. Hypersexuality in idiopathic Parkinson's disease. Clin Neuropharmacol 1989;12:375-383
85. Harvey NS. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry 1988;153:833-836
86. Quinn NP, Toone B, Lang AE, et al. Dopa dose-dependent sexual deviation. Br J Psychiatry 1983;142:296-298
87. Beardsley JV, Puletti F. Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment: outcomes in patients with Parkinson's disease. Arch Neurol 1971;25:145-150
88. Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991;84: 111-113
89. Todes C, Lees A. The pre-morbid personality of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1985;48:97-100
90. Hubble JP, Koller WC. The parkinsonian personality. In: Weiner WJ, Lang AE, eds. Behavioral Neurology of Movement Disorders. New York, NY: Raven Press; 1995:43-48
91. Lieberman A. Managing the neuropsychiatrie symptoms of Parkinson's disease. Neurology 1998;50:33-38
92. Luquin MR, Obeso JA, Martinez-Lage JM, et al. Parenteral administration of lisuride in Parkinson's disease. Adv Neurol 1987;45:561-568
93. Friedman JH. Drug holidays in the treatment of Parkinson's disease: a brief review. Arch Intern Med 1985;145:913-915
94. Goetz C, Tanner CM, Klawans HL. Drug holidays in the management of Parkinson's disease. Clin Neuropharmacol 1982;5:351-364
95. Mayeux R, Stern Y, Mulvey K, et al. Reappraisal of temporary levodopa withdrawal ("drug holidays") in Parkinson's disease. N Engl J Med 1985; 313:724-728
96. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-1020
97. Guze BH, Baxter LR Jr. Neuroleptic malignant syndrome. N Engl J Med 1985;313:163-166
98. Kalish SC, Bohn RL, Mogun H, et al. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people. J Am Geriatr Soc 1995;43:967-973
99. Koller W, Silver D, Lieberman A. An algorithm for the management of Parkinson's disease. Neurology 1994;44:S1-S52
100. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57(suppl 11):4-11
101. Keck PE, McElroy SL. The new antipsychotics and their therapeutic potential. Psychiatr Ann 1997;27:320-331
102. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(suppl 11):40-45
103. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol 1985;235:60-64
104. Bernardi F. Del Zompo M. Clozapine in idiopathic Parkinson's disease [letter; comment]. Neurology 1990;40:1151-1152
105. Factor SA, Brown D, Molho ES, et al. Clozapine: a two year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44: 544-546
106. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989;39:1219-1221
107. Kahn N, Freeman A, Juncos JL, et al. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991;41:1699-1700
108. Ostergaard K, Dupont E. Clozapine treatment of drug induced psychotic symptoms in later stages of Parkinson's disease. Acta Neurol Scand 1988; 78:349-350
109. Pfeiffer RF, Kang J, Graber B, et al. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990;5:239-242
110. Rabey JM, Trevas TA, Orlov E, et al. Low dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45:432-434
111. Widman LP, Burke WJ, Pfeiffer RF, et al. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review. J Geriatr Psychiatry Neurol 1997;2:63-66
112. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12:483-496
113. Safferman AZ, Kane JM, Aronowitz JS, et al. The use of clozapine in neurologic disorders. J Clin Psychiatry 1994;55(9, suppl B):98-101
114. Wolters EC, Hurwitz TA, Mek E, et al. Clozapine in the treatment of parkinsonism patients with dopaminomimetic psychosis. Neurology 1990; 40:832-834
115. Friedman JH, and the Parkinson Study Group. Lannon MC, Factor S, et al. Low dose clozapine for the treatment of drug-induced psychosis (DIP) in idiopathic Parkinson's disease: results of the double-blind, placebo-controlled PSYCLOPS Trial. N Engl J Med. In press
116. Friedman JH, Lannon MC. Clozapine treatment of tremor in Parkinson's disease. Mov Disord 1990;5:233-238
117. Jansen ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994;89:262-265
118. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73:295-297
119. Arevalo GJG, Gershanick OS. Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 1993;8:349-354
120. Bennett JP Jr, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease, II: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43: 1551-1555
121. Bennett JP Jr, Landow ER, Dietrich S, et al. Suppression of dyskinesias in advanced Parkinson's disease. III: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-414
122. Juncos JL. Clozapine treatment of parkinsonian pain syndromes [abstract]. Mov Disord 1996;11:603-604
123. Linazasoro G, Marti Masso JF, Suarez JA. Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993;8: 171-174
124. Wagner ML, Defilippi JL, Menza MA, et al. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8:276-280
125. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994;35: 886-887
126. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-330
127. Kastrup O, Gastpar M, Schwartz M. Acute dystonia due to clozapine [letter]. J Neurol Neurosurg Psychiatry 1994;57:119
128. Miller DD, Sharafuddin MJA, Kathol RG. A case of clozapine-induced neuroleptic malignant syndrome [letter]. J Clin Psychiatry 1991;52: 99-101
129. Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986;174:493-495
130. Owens DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55(5, suppl):29-35
131. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514-518
132. Raheja RK, Bharwani I, Penetrante AE. Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. J Geriatr Psychiatry Neurol 1995;8:159-161
133. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997;9:65-68
134. Sajatovic M, Ramirez LF, Vernon L, et al. Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 1996;26:309-317
135. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients [letter]. Lancet 1994; 343:1370-1371
136. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter; comment]. Lancet 1994;344:681
137. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559
138. Beasley CM, Sanger T, Satterlee WG, et al. Olanzapine versus placebo: results of a double-blind fixed-dose trial. Psychopharmacology 1996; 124:159-167
139. Tran P, Hamilton S, Kuntz A, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
140. Wong DT, Calligaro DO, Bymaster FP, et al. Preclinical pharmacology of olanzapine: a novel antipsychotic agent. Presented at the 9th World Congress of Psychiatry; June 6-12, 1993; Rio de Janeiro, Brazil
141. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53:281-298
142. Beasley CM, Tran PV, Tamura RN, et al. Olanzapine versus haloperidol: results of the multi-center international trial. Presented at the 34th annual meeting of the American College of Neuropsychopharmacology; December 11-14, 1995; San Juan, Puerto Rico
143. Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry 1997;58(suppl 10):18-21
144. Kane JM. The new antipsychotics. J Pract Psych Behav Health 1997;3: 343-355
145. Wolters EC, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087
146. Fahn S, Elton RL, and the members of the UPRS Development Committee. Unified Parkinson's Disease Rating Scale. New York, NY: Macmillan; 1987:153-173
147. Musser WS, Akil M. Clozapine as a treatment for psychosis in Parkinson's disease: a review. J Neuropsychiatry Clin Neurosci 1996;8:1-9
148. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel): a dibenzothiazepine atypical antipsychotic: review of preclinical pharmacology and highlights of Phase II clinical trials. CNS Drug Rev 1995;1:50-73
149. Small JG, Hirsch SR, Arvanitis LA, et al., and The Seroquel Study Group. Quetiapine in patients with schizophrenia a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
150. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:255-275
151. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
152. Goldstein JM, Arvanitis LA. Seroquel (quetiapine) is not associated with dose-related extrapyramidal symptoms: overview of clinical results [abstract]. Schizophr Res 1997;24:198
153. Saller CF, Salama AL. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:285-292
154. Arvanitis LA, Rak IW. The long-term efficacy and safety of Seroquel (quetiapine) [abstract]. Schizophr Res 1997;24:196
155. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999;60(suppl 8):29-41
156. Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 1999;60(suppl 8): 21-28
157. Smith D, Pantelis C, McGrath J, et al. Ocular abnormalities in chronic schizophrenia: clinical implications. Aust N Z J Psychiatry 1997;31: 252-256
158. McManus DQ, Arvanitis LA, Kowalcyk BB, and the Seroquel Trial 48 Study Group. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry. In press
159. Juncos JL, Evatt ML, Jewart D. Long-term effects of quetiapine fumarate in parkinsonism complicated by psychosis. Neurology 1998;50:70-71
160. Parsa MA, Bastani B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1998;10:216-219
161. Rosenfeld MJ, Friedman JH, Jacques C. Quetiapine pilot trial in dopaminomimetic psychosis (DP) in Parkinson's disease (PD). Presented at the International Congress on Parkinson's Disease and Movement Disorders; October 10-14, 1998; New York, NY